About evogene ltd - EVGN
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.
EVGN At a Glance
Evogene Ltd.
13 Gad Feinstein Street
Rehovot, HaMerkaz 7638517
| Phone | 972-8-931-1900 | Revenue | 3.85M | |
| Industry | Biotechnology | Net Income | -8,485,000.00 | |
| Sector | Health Technology | Employees | 52 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
EVGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.248 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.769 |
| Enterprise Value to Sales | 2.577 |
| Total Debt to Enterprise Value | 0.221 |
EVGN Efficiency
| Revenue/Employee | 74,096.154 |
| Income Per Employee | -163,173.077 |
| Receivables Turnover | 8.198 |
| Total Asset Turnover | 0.129 |
EVGN Liquidity
| Current Ratio | 4.379 |
| Quick Ratio | 4.318 |
| Cash Ratio | 3.771 |
EVGN Profitability
| Gross Margin | 22.32 |
| Operating Margin | -363.275 |
| Pretax Margin | -349.312 |
| Net Margin | -220.218 |
| Return on Assets | -47.261 |
| Return on Equity | N/A |
| Return on Total Capital | -669.045 |
| Return on Invested Capital | -1,519.807 |
EVGN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 103.875 |
| Total Debt to Total Assets | 10.965 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 70.038 |